NCT00782951终止2 期
A Randomized, Double-blind, Active and Placebo Controlled Trial to Compare the Relative Analgesic Efficacy and Safety of a Single Intravenous Dose of ORG 28611 3 mcg/kg, Morphine Sulfate 0.12 mg/kg, and Placebo in Patients Experiencing Moderate to Severe Pain After Dental Impaction Surgery.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 11
- 主要终点
- Total Pain Relief Score (TOTPAR)
研究概览
简要总结
Patients will receive a single intravenous (IV) infusion administered over 3 minutes of either ORG 28611 (SCH 900111), 0.12 mg/kg morphine sulphate, or placebo, within 6 hours after dental surgery, when they experience moderate to severe dental pain. Patient will then be evaluated with pain assessments at Baseline, 5, 10, 15, 30, 45, 60, and 90 minutes; and 2 through 8 hours or before rescue medication is needed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Has at least one mandibular partial or full bony impacted third molar requiring extraction. An ipsilateral maxillary third molar may also be extracted as may any adjacent supernumerary tooth (teeth)
- •Is willing and able to understand and complete the pain evaluations
- •Is male aged 18 to 40 years (inclusive)
- •A subject, who has sexual partners of child-bearing potential, has agreed to use barrier contraception in addition to having their partner use another method for three months from the time of dosing. Also has agreed to abstain from sexual intercourse with pregnant or lactating women or to use condoms.
- •Has a body mass index (BMI) less than or equal to 32 kg/m^2 and has a body weight of at least 65 kg
- •Is in generally good health
- •Is able to speak, read, and understand English and provide meaningful written informed consent
- •Is able to remain at the research center for the entire 24-hours trial period
- •Has an initial pain intensity score of at least 45-mm on a 100-mm VAS and moderate or severe pain on a 4-point categorical scale within 6 hours of the end of surgery (VAS as the primary parameter and the categorical as a secondary parameter)
- •Is willing to return to the research center for the post-treatment visit 5 to 9 days after surgery and complete a day 30 SAE telephone call.
排除标准
- •Has uncontrolled or clinically significant cardiovascular, respiratory, gastrointestinal, renal, hepatic, metabolic, hematological, or immunological disease
- •Has a history of seizures, a family history of seizure disorder, or psychotic illness
- •Has a known allergy or significant adverse reaction to opioids or opioid antagonists, paracetamol or ibuprofen
- •Has a history of chronic opioid or cannabis use or abuse within 6 months prior to the start of this trial
- •Has a positive urine drug test at screening or prior to surgery
- •Has participated in a trial of an investigational drug or device within 30 days prior to the trial
- •Has taken any of the following drugs within 4 hours or 5 elimination half-lives (whichever is greater) prior to dosing: aspirin, acetaminophen (paracetamol), nonsteroidal anti-inflammatory drugs (NSAIDs, COX-2 inhibitors), opioids, opioid combination drugs, sedative-hypnotics, muscle relaxants, and/or sedating antihistamines
- •Has taken a long-acting analgesic (e.g., naproxen or celecoxib) or central nervous system (CNS) depressant within 12 hours prior to dosing
- •Has taken a monoamine oxidase (MAO) inhibitor or tricyclic antidepressant drug within 4 weeks prior to administration of trial medication
- •Has taken a selective serotonin or norepinephrine reuptake inhibitor (SSRI or SNRI) within 4 weeks prior to the start of the trial
- •Has a medical or psychiatric condition which compromises the patient's ability to give informed consent or appropriately complete the pain assessments.
- •Has an abnormal clinically significant EEG and/or an EEG indicating possible seizure(-like) disorder according to the following abnormalities (with or without clinical significance):
- •spike and wave activity (epileptiform activity)
- •paroxysmal activity
- •abnormal slowing
- •abnormal beta activity
- •asymmetry right-left and anterior-posterior not within normal limits at screening
- •Has had alcohol or caffeine in any form during 24 hours before the surgery
- •Has abnormal laboratory results at the screening which in the opinion of the
- •investigator are exclusionary.
研究组 & 干预措施
Org 28611
Experimental
干预措施: Org 28611 (Drug)
morphine sulfate
Active Comparator
干预措施: morphine sulfate (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Total Pain Relief Score (TOTPAR)
时间窗: from 0 to 4 hours
次要结局
- Time to rescue medication, time to perceptual and meaningful pain relief (stopwatch), time to onset of analgesia, Peak Pain Intensity Difference (PPID), Peak Pain Relief (PPR).(After surgery)
- Summed pain intensity difference (SPID) calculated using PID categorical scale and PID VAS scale, Summed pain relief intensity difference (SPRID),(Over 2, 4, 6, and 8-hour intervals)
- Global evaluation of trial medication on a 5-point categorical scale at 8 hours or just prior to rescue medication(at 8 hours or just prior to rescue medication)
- Pain Intensity (PI) on a visual analog scale (VAS), PI difference in VAS from Baseline, PI difference on a categorical scale, PI difference on categorical scale from Baseline, Pain Relief (PR) on a categorical scale, PR Intensity Difference (PRID).(at Baseline, 5, 10, 15, 30, 45, 60, and 90 minutes; and 2 through 8 hours or before rescue medication)
- TOTPAR(over 2, 6, and 8-hour intervals)
研究者
相似试验
已完成
3 期
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid ArthritisRheumatoid ArthritisNCT00152386UCB Pharma950
进行中（未招募）
Unknown
A single dose three-way crossover oral bioavailability study of ß-alanine capsules in comparison with conventional ß-alanine in healthy human volunteers in fasting conditionsCTRI/2024/03/063457atural Alternatives International
已完成
1 期
Clinical Trial of AVL-3288 in Schizophrenia PatientsSchizophreniaSchizoaffective DisorderNCT02978599New York State Psychiatric Institute24
已完成
3 期
A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee PainOsteoarthritis, KneeNCT03429049Centrexion Therapeutics332
已完成
3 期
Nasal Gel for the Prevention of Nausea and Vomiting Associated With MotionMotion SicknessNCT04947423Repurposed Therapeutics, Inc.140